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ABSTRACT
Infection of Megalocytivirus cause serious mass mortality in marine fish in South East Asian countries. The
aim of this study was to produce recombinant of GSDIV capsid protein and its protection to humpback
grouper Cromileptes altivelis against grouper sleepy disease iridovirus (GSDIV). A major capsid protein (MCP)
was selected for use as a crude subunit vaccines. This gene target (MCP) was inserted to the protein
expression system vector of pET SUMO and cloned in cells bacteria Escherichia coli strain BL-21. The MCP
was succeded to be induced using 1 mM of IPTG. Results of protein analysis using MALDI TOF-TOF
indicated that the MCP has measurement of 49.566 kDa with PI index of 6.00, and contained 453 amino
acids. BLAST homology analysis exhibited that the amino acid sequence of the MCP showed high similarity
with MCP of Red Sea Bream Iridovirus (RSIV). E. coli expressing MCP protein was inactivated using 0.03%
formalin overnight and washed using PBS. The inactivated E. coli as a crude subunit vaccine was then
injected intramuscularly to humpback grouper juveniles. Subsequently, the juveniles were challenged
tested with GSDIV. The juveniles vaccinated with the MCP recombinant bacteria showed significantly higher
survival rates than control those vaccinated with PBS. Thus, the MCP fusion protein is considered as a
potential vaccine against GSDIV infections in grouper.
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INTRODUCTION
In Indonesia, Megalocytivirus have been reported
to infect and caused mass mortality in marine fish
such as orange-spotted grouper Epinephelus coioides
(Koesharyani et al., 2001; Mahardika et al., 2001; 2003),
humpback grouper Cromileptes altivelis (Mahardika et
al., 2004), tiger grouper E. fuscoguttatus, malabar grou-
per E. polyphekadion, coral trout grouper Plectropomus
indicus (Mahardika et al., 2009b), sea bass Lates
calcarifer (Mahardika & Mastuti, 2010), and cobia
Rachycentron canadum (Mahardika, personal commu-
nication). Recently, this disease is supposed to cause
“drop scale disease” in barramundi in Batam island
(Sunarto, personal communication). Megalocytivirus are
also reported to infect freshwater fish such as dwarf
gourami Colisa lalia, African lampeye Aplocheilichthys
normani cultivated in Sumatra and exported to Japan
via Singapore (Sudthongkong et al., 2002a), gourami
Osphronemus gourami and tilapia Osteochillus hasselti
(Koesharyani, personal communication).
An effective and efficient drug for treatment of
viral diseases has not been found. Antibiotics and
vitamins were used to prevent secondary infections
and boost the general immune system of fish. Fur-
thermore, addition of omega interferon and liquid
filtration of the spleen from diseased fish on RSIV
pure virus (in vitro) has not been able to inhibit the
proliferation of the virus in cells (Mahardika &
Miyazaki, 2009). Therefore, an early prevention us-
ing a specific vaccine for the Megalocytivirus disease
is required. Prevention of Megalocytivirus infections
has been successfully carried out by administration
of inactivated vaccine and DNA-RSIV vaccine (Nakajima
et al., 1997; 1999; Caipang et al., 2006). Vaccination
has also been successfully performed on humpback
grouper in preventing GSDIV infection by commer-
cial vaccine (Biken, Japan) (Mahardika et al., 2008).
However, the price of the vaccine is very expensive
which is imported from Japan. Vaccinations using in-
activated GSDIV virus which isolated from diseased
fish organs or virus resulting from proliferation in
cultured Grunt Fin (GF) cells have been successful in
reducing the mortality of grouper to GSDIV viral in-
fections in a laboratory (Mahardika et al., 2010; un-
published data). However, the crude GSDIV virus from
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diseased fish organs are not reliable continuously in
large quantities and or GSDIV virus cannot develop
optimally on GF cells characterized by the virus titer
that is still very unstable. Therefore, it is required to
apply recombinant technology methods for mass sup-
ply of GSDIV vaccine.
Production of vaccine is currently supported by
the technology of recombinant proteins, by insert-
ing the virus genes to be expressed in the host cell.
This technology provides several advantages i.e. it
does not require viral culture, the possibility to se-
lect specific proteins, and economiccally of mass-scale
production. Institute for Mariculture Research and
Development (IMRAD), Gondol was obtained a DNA
library GSDIV capsid protein gene, and constructed
this gene to the expression vector. The targetted
gene was chosen based on previous study that the
MCP gene is conserved region and plays a role in
pathogenicity of the megalocytivirus virus
(Sudthongkong et al., 2002b; Shimmoto et al., 2010).
The aim of this study was to produce a recombinant
capsid protein GSDIV and its protection to hump-
back grouper against GSDIV infection.
MATERIALS AND METHODS
E. coli Strain, Virus Stock and DNA Preparation
Escherichia coli strains MACH1™ -T1R and BL21(DE3)
were obtained commercially (Invitrogen, Cat. No.
C8620-03 and C6000-03). The pET SUMO vector
(Invitrogen, Lot. no. 841075) has been described pre-
viously (Lee et al., 2008). E. coli manipulations were
performed according to the manufacturers instruc-
tions. The standard DNA and protein analysis were
carried out as described by Sambrook et al. (1989).
The virus was obtained from the spleen and kid-
neys of naturally infected fish. Spleen and kidneys
were homogenized in nine times of the volume of
EMEM-2 and centrifuged at 3,000 rpm for 15 min-
utes. The supernatant was filtered at 0.45 ìm2. The
filtrate is stored in -80°C and used as a source of the
DNA template, vaccine trials, and propagation of the
virus in healthy fish.
Construction of Bacterial Expression Vector
Viral DNA was extracted from the virus pellet us-
ing a lysis buffer according to the protocol (IQ2000TM
kit). Amplification of genomic DNA using Go Taq PCR
Core System I kit (Promega, Cat. M7660) with the
primer design of DNA sequences capsid protein MCP
RSIV (AB666334.1) with sequences 5
‘ATGTCTGMRATCTCAGGTGCRAACG’3 (MCPBP), and
5' TTACAGGATAGGGAAGCCTGCAGCG ‘3 (MCPFP)
with a weight of 1,362 bp. The MCP gene amplifica-
tion was carried out in 30 cycles (denaturation tem-
perature of 94°C for 1 minute, annealing tempera-
ture of 55°C for 1 minute and extension temperature
of 72°C for 1 minute for one cycle), followed by de-
naturation temperature of 94°C for 1 minute and 72°C
during the final extention for 7 minutes, and the cool-
ing temperature of 4°C for 5 minutes. The resulting
amplicons were visualized in agarose gel 1.5 % in TAE
1x.
PCR product was purified using a PCR purification
kit (Roche, Cat. No. 11732668001) and visualized in
agarose gel (1.5 % in TAE 1x) to get a purify and single
band. The purificated DNA was then ligated to the
vector pET SUMO (Champion™ pET SUMO, Invitrogen)
according to the protocol, briefly 2 mL of PCR prod-
uct was mixed with 1 mL of 10x ligase buffer, 2 mL of
vector pET SUMO, 1 mL of T4 DNA ligase and sterile
water to a total volume of 10 mL, and then incubated
at 15°C overnight. The ligation product was trans-
formed in bacteria Eschericia coli strain Mach1™ -T1R.
The process of transformation was done by heat-
shock method, i.e. incubating 2 mL of mixture liga-
tion and 50 mL of competent cells in crushed ice for
20 minutes, then heated in a water bath temperature
of 42°C for 40 seconds and then quickly moved in ice
to be added to 250 mL of growth medium SOC (su-
per optimal catabolite expression). The transforma-
tion solution was grown for 1 hour at 37°C with a
speed of 200 rpm in automatic incubator shaker. Re-
sult of the growth of these cells was cultured in LB
agar medium containing kanamycin 50 mg/mL. Sub-
sequently, any colonies that grew were taken to be
grown in 10 ml LB broth media containing kanamycin
50 mg/mL. As a stock, a total of 0.85 mL of LB broth
containing bacteria was mixed with 0.15 mL of ster-
ile glycerin and stored at -80°C. Colonies that can
grow in LB broth containing kanamycin 50 mg/mL in-
dicated that the competent cells carrying a recombi-
nant plasmid. To determine the orientation of inser-
tion of the targetted gene was done by PCR and gene
sequence analysis. The recombinant plasmid was ex-
tracted using a plasmid minispin prepease kit (USB,
Lot. 1104/001). The PCR amplification to determine
the orientation of the insertion of genes MCP (SUMO
primer pairs forward and MCPBP) was conducted in
30 cycles (denaturation temperature of 94°C for 1
min., annealing temperature of 55°C for 1 min. and
extension temperature of 72°C for 1 min. for one
cycle), continued to the denaturation temperature of
94°C for 1 min, and a final extension of 72°C for 7
min., followed by storage temperature of 4°C for 5
min. The correct orientation will result in DNA
amplicon size of 1,465 bp (according to criteria in
pET SUMO kit).
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Protein Expression
Plasmid which has been known to carry the
targetted gene with the correct orientation was then
transformed into competent cells of E. coli strain
BL21. Transformation by heat-shock method was per-
formed by incubating the recombinant plasmid and
50 mL BL21 in crushed ice for 30 minutes, then heated
in a water bath with temperature of 42°C for 40 sec.
and quickly moved into the ice to be added to 250
mL of SOC growth medium. Result of the transfor-
mation was grown for 1 hour at 37°C with a speed of
200 rpm. Transformant was grown in LB agar medium
containing kanamycin. Any colonies that grew were
cultured in 10 mL of LB broth media containing kana-
mycin for the purpose of analysis and stock.
Expression of the protein was done by inducing
BL21 culture that has reached the density of 108 cfu/
mL which determined by the absorbance value at OD600
to 1.5. A total of 10 µL stock BL21 cultures were
grown in 70 mL of LB broth containing kanamycin of
50 mg/mL with shaking of 125 rpm at 37°C. Sufficient
density was achieved after 48 hours. Then, 0.1 mM
of IPTG was added into cultured BL21 to induce pro-
tein. Induction conducted overnight. Induction re-
sults were divided into 20 mL and 50 mL to protein
analysis and used to crude inactivated subunit vac-
cine.
The presence of protein expression in BL21 was
confirmed by SDS-page. A total of 20 mL cultured
BL21 that had been induced with IPTG was centri-
fuged at 6,000 rpm for 10 min. Pellets were then lyzed
enzymatically with lysozyme and mechanically with
freeze-thawing method and sonication. Enzymatic
lysis was performed by incubating 100 µL of pellet
with 150 µL of 200 mM lysozyme at 37°C for 5 min.
Then, these cells were lyzed with freeze-thawing and
sonication (freeze at -80°C and melt at a temperature
of 42°C for 30 times, and then sonicated for 4 x 15
minutes). The cell solution was centrifuged at maxi-
mum speed for 1 min. A 10 µL of pellet and 25 µL of
supernatant were taken for the SDS-page analysis.
SDS-page sample was prepared by adding 1x sample
buffer (1.25 mL of 0.5 M Tris-CL pH 6.8, 1 mL of 100%
glycerol, 0.2 mL of beta-merkaptoethanol, 0.01 g
bromo phenol blue, 2 g SDS, and sterile distilled wa-
ter to a total volume of 10 mL) into pellet and 2x
sample buffer into the supernatant with an equiva-
lent volume. The mixture solution was heated in boil-
ing water for 5 min. and cooled at room tempera-
ture. The sample was then injected into 12% of po-
rous gel poliacrylamyde that had been prepared. On
one hole of gel was injected with 10-200 kDa protein
marker (Bio Basic Inc., Lot. 1203SH00072277R2) to
determine the molecular weight of the protein. Elec-
trophoresis was performed in a buffer containing gly-
cine for 45 min. at a voltage of 200 volts. Gel elec-
trophoresis was stained with comassie brilliant blue
(CBB) for one hour. The excess of gel color was re-
duced by soaking in the decolorizer solution (7 mL
of glacial acetic acid, 7 mL methanol, and 86 mL of
distilled water) for 30 min. with a shaker and subse-
quently allowed to stand until one night.
DNA Sequense Analysis
DNA sequencing was conducted to determine the
DNA sequence of the gene MCP-GSDIV virus. The
samples used were the result of amplification of vec-
tors that have been inserted by MCP gene in the cor-
rect orientation. PCR product was then purified by
PCR purification kit (Roche). Samples were sequenced
using the services of 1st BASE provider (Singapore).
DNA sequences were analyzed by BLAST to know its
homology, and ORF Finder for prediction of nucle-
otide acids.
Protein Analysis
The function of the target gene in expressing the
protein was confirmed by sequenzed of protein pro-
duction. The sample used for the sequencing was a
piece of band in gel electrophoresis-polyacrilamide
that showed over-expression. Protein sequencing
through a service provider (proteomics International
Pty Ltd, Australia) which uses the technique of pro-
tein digestion with trypsin, and the resulting pep-
tides were analyzed by MALDI TOF-TOF (matrix-as-
sisted laser desorption/ionization mass spectrometry
time of flight-time of flight) tandem mass spectro-
photometer (4,800 proteomics analyzer, AB Sciex).
Protein identification using Mascot software based
on data Ludwig NR. Results obtained from the pro-
vider reanalyzed by BLAST to know its homology.
Crude Protein Subunit Vaccine Preparation
A 50 pg/mL cultured of E. coli strain BL21 that had
been induced and known to express proteins (by SDS-
page) was inactivated by adding formalin to a final
concentration of 0.03%. Formalin inactivation was
carried out for one night at room temperature. For-
malin was cleared by centrifugation at 6,000 rpm for
5 min. and the pellet was lyzed by sonication (4 x 15
min.). The pellet was diluted into obtain the density
of bacteria that was equivalent to the initial density
(108 CFU/mL).
Vaccination Trials
Vaccine trials were done using juveniles of hump-
back grouper with total length of 6-8 cm. The vac-
cine was given by intramuscular injection with a dose
of 0.1 mL/fish, while control group was given PBS
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(negative control) or CAT (positive/protein control).
Vaccine trials conducted in laboratory scale (15-20
fish in aquarium with volume of 100 L) and a semi-
mass scale (100 and 150 fish in a floating net at 1 m x
1 m x 0.75 m, which floated in concrete tank). The
vaccine is given as a single and booster with inter-
vals of 7 days. GSDIV virus challenge test was done
after 14, 20, 30 days from the last vaccination. Effec-
tiveness of vaccine was determined by the value of
the relative percentage survival (RPS) after challenged
with the GSDIV virus which has a 100% lethal dose.
The data of challenge test results were presented in
the form of percent mortality and RPS (percent sur-
vival ratio) with the formula:
RESULTS AND DISCUSSION
Amplification of Gene Target
Target genes which obtained from the spleen of
diseased fish could be amplified with primers that
were designed based on the gene RSIV (red sea bream
iridovirus) in the region of the MCP. Optimization of
amplification conditions could produce amplicon with
the correct size of 1,362 bp (Figure 1). This result
indicated the gen GSDIV in the region of the MCP
have similarity with the gen RSIV. The result is re-
sembled with a previous research which claimed that
the ATPase gene and the MCP gene of SBIV (sea bass
iridovirus), RSIV (red sea bream iridovirus), GSDIV
(grouper sleepy disease iridovirus), ALIV (African
lampeye iridovirus), and DGIV (dwarf gourami
iridovirus) were highly homologous (> 95.8%, >
94.9% identity) (Sudthongkong et al., 2002b).
Cloning and Gene Exppresion
Some colonies of E. coli strain Mach1 were known
to carry the recombinant plasmid with the insertion
of targetted gene into the vector of pET SUMO. It
was shown from the result of a target gene amplifi-
cation using primer vector and primer target gene.
The amplicons exhibited 150 base pairs (total 1,512
bp) longer than the target genes due to the use of
primary vector (Figure 2).
Recombinant plasmid was expressed the protein
in cells E. coli strain BL-21 with induction of 0.1 mM
of IPTG. Results of electrophoresis with gel SDS-page
indicated that molecular weight of the recombinant
MCP was 60 kDa (Figure 3). MCP is comprised of the
outer capsid proteins with a molecular weight of ~
50 kDa. The MCP gene sequence is conserved re-
gions in members of family Iridovirus. It could be used
in basic detection of viral particles in the family of
Iridovirus (Chincar et al., 2011).
The results of proteins electrophoresis of gel
polyacrylamide was known recombinant proteins
(marked with thick band/over expression) parallel to
the 60 kDa (Figure 3). This was the effect of the fu-
sion protein SUMO (small ubiquitin-like modifier).
This was based on the results of the digestion of
proteins from the process of protein analysis by MALDI
TOF-TOF which proves that overexpression of MCP
protein carrying the 12.1 kDa of protein of Saccharo-
myces cerevisiae and MCP-GSDIV protein (49.566 kDa).
The aim of selecting the expression plasmid with
)(
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Figure 1. MCP-targetted gene in agarose gel shows the expected
amplicon size (1,362 bp.). M: 100 bp DNA ladder, (-): control
negative
M
MCP
1 2 3 ( - )
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SUMO fusion was to improve the solubility of ex-
pressed proteins that was easy to be isolated (Der et
al., 2008). Further expected protein could be obtained
by partially solving of cells through sonication to be
used as a crude subunit vaccine.
Sequence of the DNA Gene Target
MCP gene sequencing was obtained partial nucle-
otide sequences (partial cds), i.e. 1,226 of 1,362 nucle-
otides (Figure 4). BLAST homology analysis showed
that the gene MCP-GSDIV have similarity up to 99%
with the other isolates Megalocytivirus as shown in
Table 1. Sequences producing significant alignments:
MCP-encoding gene was known with size of
1,362-1,372 bp and encodes 454 amino acids. The
gene revealed a highly identical (> 97.2% identity)
with some isolates of Megalocityvirus namely SBIV,
RSIV, GSDIV, ALIV, DGIV (Sudthongkong et al., 2002b).
Sequence of Protein
Peptide analysis with MALDI-TOF-TOF showed
that recombinant MCP-GSDIV expressed a protein
fusion MCP and modification protein from vector. The
molecular size of MCP was 49.566 kDa with PI value
of 6.00, while the modification protein of vector was
12.1 kDa (Figure 5). Peptide identification based on
Figure 2. PCR confirmed a recombinant plas-
mid for correct orientation using
plasmid forward primer and
targetted gene backward primer. M:
100 bp DNA ladder M
Figure 3. SDS-page gel shows protein expression
of MCP gene
M 1 2
CAT MCP
4 3
MCP
M
70 kDa
60 kDa
50 kDa
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Table 1. Some isolates Megalocytivirus that have similarities with gene MCP-GSDIV
Figure 4. Partial coding sequence (partial cds) of gene
encoding MCP-GSDIV
Accession Description
Maximal 
score
Total 
score
Query 
coverage
E value
Max 
ident
JQ253372.1 Megalocytivirus Sabah/RAA/2012 strain OSGIV75 
major capsid protein gene, complete cds
2254 2254 99% 0.0 99%
HQ317465.1 Infectious spleen and kidney necrosis virus isolate ISKNV-DW 
major capsid protein (mcp) gene, complete cds
2254 2254 99% 0.0 99%
AF371960.1 Infectious spleen and kidney necrosis virus, complete genome 2254 2254 99% 0.0 99%
AY285745.1 African lampeye iridovirus major capsid protein gene, complete cds 2248 2248 99% 0.0 99%
AB109369.1 Dwarf gourami iridovirus gene for major capsid protein, complete cds 2231 2231 99% 0.0 99%
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Query 1 MSAISGANVTSGFIDISAFDAMETHLYGGDNAVTYFARETVRSSWYSKLPVTLSKQTGHA 60
  MSAISGANVTSGFIDISAFDAMETHLYGGDNAVTYFARETVRSSWYSKLPVTLSKQTGHA
Sbjct 1 MSAISGANVTSGFIDISAFDAMETHLYGGDNAVTYFARETVRSSWYSKLPVTLSKQTGHA 60
Query 61 NFGQEFSVTVARGGDYLINVWLRVKIPSITSSKENSYIRWCDNLMHNLVEEVSVSFNDLV 120
  NFGQEFSVTVARGGDYLINVWLRVKIPSITSSKENSYIRWCDNLMHNLVEEVSVSFNDLV
Sbjct 61 NFGQEFSVTVARGGDYLINVWLRVKIPSITSSKENSYIRWCDNLMHNLVEEVSVSFNDLV 120
Query 121 AQTLTSEFLDFWNACMMPGSKQSGYNKMIGMRSDLVGGITNGQTMPAAYLNLPIPLFFTR 180
  AQTLTSEFLDFWNACMMPGSKQSGYNKMIGMRSDLVGGITNGQTMPAAYLNLPIPLFFTR
Sbjct 121 AQTLTSEFLDFWNACMMPGSKQSGYNKMIGMRSDLVGGITNGQTMPAAYLNLPIPLFFTR 180
Query 181 DTGLALPTVSLPYNEVRIHFKLRRWEDLLISQSTQADMAISTVTVANIGNVTPALTNVSV 240
  DTGLALPTVSLPYNEVRIHFKLRRWEDLLISQSTQADMAISTVTVANIGNVTPALTNVSV
Sbjct 181 DTGLALPTVSLPYNEVRIHFKLRRWEDLLISQSTQADMAISTVTVANIGNVTPALTNVSV 240
Query 241 MGTYAVLTSEEREVVAQSSRSMLIEQCQVAPRVPVTPVDNSLVHLDLRFSHPVKALFFAV 300
  MGTYAVLTSEEREVVAQSSRSMLIEQCQVAPRVPVTPVDNSLVHLDLRFSHPVKALFFAV
Sbjct 241 MGTYAVLTSEEREVVAQSSRSMLIEQCQVAPRVPVTPVDNSLVHLDLRFSHPVKALFFAV 300
Query 301 KNVTHRNVQSNYTAASPVYVNNKVNLPLLATNPLSEVSLIYENTPRLHQMGVDYFTSVDP 360
  KNVTHRNVQSNYTAASPVYVNNKVNLPLLATNPLSEVSLIYENTPRLHQMGVDYFTSVDP
Sbjct 301 KNVTHRNVQSNYTAASPVYVNNKVNLPLLATNPLSEVSLIYENTPRLHQMGVDYFTSVDP 360
Query 361 YYFAPSMPEMDGVMTYCYTLDMGNINFMGSTNYGRLSNVTLSCKVSDNakttaaggggng 420
  YYFAPSMPEMDGVMTYCYTLDMGNINFMGSTNYGRLSNVTLSCKVSDNAKTTAAGGGGNG
Sbjct 361 YYFAPSMPEMDGVMTYCYTLDMGNINFMGSTNYGRLSNVTLSCKVSDNAKTTAAGGGGNG 420
Query 421 tgytvaQKFELVVIAVNHNIMKIADGAAGFPIL 453
  TGYTVAQKFELVVIAVNHNIMKIADGAAGFPIL
Sbjct 421 TGYTVAQKFELVVIAVNHNIMKIADGAAGFPIL 453 
the its spectra showed that MCP was completely ex-
pressed and the peptide sequence of MCP was simi-
lar to MCP has MCP-LYCIV (large yellow croake
iridivirus) and MCP-GSIV (giant Seaperch iridovirus).
This was supported by the results of BLAST analysis
that showed 99% similarity with MCP of red sea bream
iridovirus (gi | 29,467,056 | BAC66968.1), MCP-in-
fectious spleen and kidney necrosis virus (gi | 315
454 520 | ADU25248.1), MCP-grouper sleepy disease
iridovirus (gi | 30,909,113 | AAP37443.1), MCP-in-
fectious spleen and kidney necrosis virus (gi |
57,233,193 | AAW48183.1).
MCP gene was expressed completely, producing
peptides with amino acid number of 453. The amino
acid sequence was similar to the MCP-RSIV (gi |
29,467,056 | BAC66968.1). These results are re-
sembled with MCP-Iridovirus gene sequences iso-
lated from the South China Sea and South East Asian
countries. The MCP-Iridovirus gene consists of 1,362
and 1,372 base pairs and encodes a 454 amino acid
(Sudthongkong et al., 2002b). The analysis of the nucle-
otide and amino acid sequences had visible result of
mutual support. Therefore, it can be concluded that
the targetted gene expressed the expected protein.
Vaccination Test on Humbuck Grouper
Vaccine indicated that the MCP gene was poten-
tial to induce fish immunity against GSDIV. In a labo-
ratory scale test (Table 2) with challenged by isolates
GSDIV that has a 100% lethal dose, a crude subunit
vaccine resulted a value of RPS to 54.58%. In a semi-
mass scale test (Table 3), GSDIV infection does not
occur naturally, thus, GSDIV infection was done ex-
perimentally at 20 fish. Results of the challenge test
showed that the crude subunit vaccine achieved RPS
value of 100% during the 21 days post final vaccina-
tion. However, the RPS values decreased after 30 days
post final vaccination. This condition was worsened
by a bacterial infection that causes tail root (Figure
6). The effects of booster vaccine with an interval of
7 days from the initial vaccine has not shown an in-
crease in the value of RPS after challenge with the
virus GSDIV after 30 days post booster vaccine.
The vaccinated fish showed different growth dur-
ing the vaccination period. All groups were assumed
to have same initial weight (8.86 g). The fish vacci-
nated by the crude subunit vaccine indicated the best
growth rate with the average weight of 29.2 g and
Figure 5. Amino acid sequence alligment with other highly homolog MCP Megalocityvirus
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29.0 g at the end of the vaccination period. This value
is higher than those of the control group which was
injected by the crude protein SUMO CAT vaccine i.e.
26.7%.
Some isolates of Megalocityvirus have been known
as a complete genome such as ISKNV (AF371960),
RSIV-Ehime1 strain (BD143114, AB104413), rock
bream iridovirus (RBIV) (AY532606), orange-spotted
grouper iridovirus (OSGIV) (AY894343), TRBIV
(GQ273492) and large yellow croaker iridovirus (LYCIV)
(AY779031). Based on the complete genome, struc-
ture of MCP RSIV-Ehime strain was known to be the
genes that are common to Megalocityvirus (Kurita &
Nakajima, 2012). Some capsid protein encoding ORF
on Megalocytivirus genome have been developed as a
vaccine, such as ORF and ORF 7L 11L which are the
gene encoding the structural proteins of the capsid
Megalocytivirus (Lua et al., 2005). Instead of MCP has
been used as a recombinant protein vaccine
(Shimmoto et al., 2010).
Figure 6. Bacterial infection within challenge test period at 30 day post
final vaccination experiment, Bacterial infection caused fin root
disease (A); bacteria grew on TCBSA (B)
Table 2. RPS value of the crude subunit vaccine at laboratory ex-
perimental scale
 A B 
Table 3. RPS value of the crude subunit vaccine at semi-mass experimental scale
Mortality (%) RPS (%) Mortality (%) RPS (%)
MCP 1 40.87 54.58 75.66 24.44
CAT (+ control) 90 0 100 0,00
PBS (- control) 90 - 100 -
Treatments
14 Days post final 
vaccination
21 Days post final 
vaccination
Mortality (%) RPS (%) Mortality (%) RPS (%) Mortality (%) RPS (%) Mortality (%) RPS (%)
137.660010----PCM
CAT (positive/ 
protein control)
- - - - 15 0 96.7 0
MCP 39.2 15 40 56 75 16.7 80 7,7
PBS (negative control) 46 0 90 0 90 0 86.7 0
2
1
Trial Treatments
Days after fin 
root infection
Days post final vaccination
Until 22 days 14 days 20 days 30 days
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This study utilised a crude subunit MCP protein
vaccine which was expected to modulate specific
immune system controlled by recombinant MCP pro-
tein, and non-specific immune system of fish con-
ducting by owned bacteria protein, supported by the
research result of Shimmoto et al. (2010). MCP vac-
cine has the potential to induce specific immune sys-
tem that reflected by the value of the RPS. In another
study, the increase in specific immunity was also
achieved when the recombinant RSIV vaccine was used
to alleviate RSIV infection, signified by the increase
in serum antibody and expression of MHC class 1
which is display intracellular proteins to cytotoxic T
cells (CTLs), and also present peptides generated
from exogenous proteins (Caipang et al., 2006).
Results of the vaccination in the laboratory scale
and or semi-mass scale showed a good protective
effect in 14 days post vaccination. However, this good
protective effect started to decline at days of 20-21.
This result suggested that the protection period of
the vaccination using subunit MCP protein vaccine
by single or double (booster) apllication with an in-
terval of 7 days are still short. Therefore, it is re-
quired to apply booster vaccine at 14-20 days after
the first vaccination. This booster vaccine is intended
to maintain high immunity level after 14 days post
vaccination. In addition, Adjuvants could also be added
to the vaccine to improve the efficacy and stability of
the vaccine formulations to give a longer period of
protection. Further research needs to be done to
improve the protection period by addition of adju-
vants.
CONCLUSION
GSDIV gene encoding region of the MCP had suc-
cessfully cloned into the expression plasmid. MCP
gene was well expressed and the corresponding pro-
tein was obtained. Application of recombinant pro-
teins as a crude subunit vaccine was potential to in-
duce the immune system that reflected by the RPS
value, although it provides short protection period
(14-20 days).
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